# A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis

> **NCT03613571** · PHASE2 · TERMINATED · sponsor: **TikoMed AB** · enrollment: 13 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** ILB

## Key facts

- **NCT ID:** NCT03613571
- **Lead sponsor:** TikoMed AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-15
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-08-20
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Inclusion was stopped with 13 of 15 patients recruited according to protocol. Patients responded with no safety signals. Study stop was due to slow recruitment.
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03613571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03613571, "A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03613571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*